Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9144039 | 0.79 | ALDH1A1 (0.52) | ALDH1A1CYP3A4TSHRCALM1CYP1A2 | |
| SCHEMBL2561056 | 0.78 | TAAR1 (0.55) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL19700095 | 0.77 | IDO1 (0.52) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL4890253 | 0.73 | IDO1 (0.46) | IDO1CA1CA2CA9AGXT | |
| SCHEMBL855864 | 0.73 | TP53 (0.43) | IDO1CA2TAAR1ALDH1A1TP53 | |
| SCHEMBL5326580 | 0.73 | IDO1 (0.58) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL31385677 | 0.72 | CA2 (0.61) | CA2ALDH1A1ALOX15CYP3A4ALOX12 | |
| SCHEMBL31385691 | 0.72 | LMNA (0.41) | ALDH1A1ALOX15ALOX12SMN1; SMN2SLC6A4 | |
| SCHEMBL27884 | 0.72 | LTA4H (0.81) | IDO1CA12CA1CA2CA7 | |
| SCHEMBL834551 | 0.72 | TAAR1 (0.73) | IDO1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20150094348-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CT CARDIOLOGICO MONZINO S P A (IT) | 2015-04-02 | — | — | US | disclosed |
| US-20150094348-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CT CARDIOLOGICO MONZINO S P A (IT) | 2015-04-02 | — | — | US | disclosed |
| EP-2635275-B1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CT CARDIOLOGICO MONZINO SPA (IT) | 2014-08-06 | — | — | EP | disclosed |
| US-20140148472-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CENTRO CARDIOLOGICO MONZINO SPA (IT) | 2014-05-29 | — | — | US | disclosed |
| US-20140148472-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | CENTRO CARDIOLOGICO MONZINO SPA (IT) | 2014-05-29 | — | — | US | disclosed |
| EP-2635275-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Centro Cardiologico Monzino SpA (IT) | 2013-09-11 | — | — | EP | disclosed |
| US-8258156-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-09-04 | — | — | US | disclosed |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2012-08-02 | — | — | US | disclosed |
| US-8153635-B2 | Compounds and compositions as modulators of GPR119 activity | IRM LLC (BM) | 2012-04-10 | — | — | US | disclosed |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC, a Delaware Limited Company (BM) | 2011-09-15 | — | — | US | disclosed |
| WO-2009145721-A1 | ISOINDOLINE DERIVATIVES COMPRISING PHENYL GROUPS AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009145718-A1 | ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2009-10-29 | — | — | US | disclosed |
| EP-0921116-B1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | HOFFMANN LA ROCHE (CH) | 2003-06-18 | — | — | EP | disclosed |
| US-6140353-A | USED AS MEDICAMENTS FOR THE TREATMENT AND/OR PREVENTION OF THROMBOSES, APOPLEXY, CARDIAC INFARCTION, INFLAMMATION AND ARTERIOSCLEROSIS OR AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. (US) | 2000-10-31 | — | — | US | disclosed |
| EP-0921116-A1 | N-(4-carbamimido-phenyl)-glycine amide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
| US-5403574-A | Evaluation and treatment of the multidrug resistance phenotype | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1995-04-04 | — | — | US | disclosed |
| WO-1993000064-A2 | EVALUATION AND TREATMENT OF THE MULTIDRUG RESISTANCE PHENOTYPE | BRIGHAM AND WOMEN'S HOSPITAL (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148472-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | GPR65, GPR17, GPR27 | IDO1 2979/4885CA12 3292/4885CA1 2841/4885 |
| US-20110224185-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | IDO1 3041/4885CA12 4286/4885CA1 4426/4885 |
| US-20150094348-A1 | GPR17-MODULATING COMPOUNDS, DIAGNOSTIC AND THERAPEUTIC USES THEREOF | GPR65, GPR17, GPR27 | IDO1 2979/4885CA12 3292/4885CA1 2841/4885 |
| US-20090270409-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | IDO1 3041/4885CA12 4286/4885CA1 4426/4885 |
| US-20120196844-A1 | COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY | GPR119, GPR65, GPR39 | IDO1 3041/4885CA12 4286/4885CA1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.